This indicates that ABCB1‐mediated effects have limited impact on the tyrosine kinase inhibitor response profiles in our panel of EGFR tyrosine kinase‐adapted NSCLC sublines. The gene discussed is ABCB1; the disease is non-small cell lung carcinoma.